f Multi-Drug-Resistant Tuberculosis: A Global Health Crisis in the Making

References

1. TiberiS. UtjesanovicN. GalvinJ. Drug-resistant TB - latest developments in epidemiology, diagnostics, and management.Int. J. Infect. Dis.20221241242510.1016/j.ijid.2022.03.026
   [Google Scholar]
2. World Health OrganizationTuberculosis deaths and disease increase during the COVID-19 pandemic.Available from: https://www.who.int/news/item/27-10-2022-tuberculosis-deaths-and-disease-increase-during-the-covid-19-pandemic 2022
3. IchsanI. Redwood-CampbellL. MahmudN.N. Risk factors of MDR-TB and impacts of the COVID-19 pandemic on the escalating incidence of MDR-TB in lower-middle-income countries: A scoping review.Narra J202332113
   [Google Scholar]
4. SchamiA. IslamM.N. BelisleJ.T. Drug-resistant strains of Mycobacterium tuberculosis: cell envelope profiles and interactions with the host.Front. Cell. Infect. Microbiol.20231311410.3389/fcimb.2023.1274175
   [Google Scholar]
5. KhawbungJ.L. NathD. ChakrabortyS. Drug-resistant tuberculosis: a review.Comp. Immunol. Microbiol. Infect. Dis.20217410157410.1016/j.cimid.2020.101574
   [Google Scholar]
6. MiglioriG.B. TiberiS. ZumlaA. PetersenE. ChakayaJ.M. WejseC. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network.Int. J. Infect. Dis.202092S15S2510.1016/j.ijid.2020.01.042
   [Google Scholar]
7. WellsC. SevernM. Incentives and support programs to improve adherence to tuberculosis treatment.Ottawa (ON)Canadian Agency for Drugs and Technologies in Health2021
   [Google Scholar]
8. TuH-A. VuH.D. RozenbaumM.H. A literature review on the economics of vaccination against TB.Expert Rev. Vaccines201211330331710.1586/erv.11.197
   [Google Scholar]
9. HarriesA.D. KumarA.M.V. SatyanarayanaS. The growing importance of tuberculosis preventive therapy and how research and innovation can enhance its implementation.Trop. Med. Infect. Dis.202052616210.3390/tropicalmed5020061
   [Google Scholar]
10. YusoofK.A. GarcíaJ.I. SchamiA. Tuberculosis phenotypic and genotypic drug susceptibility testing and immunodiagnostics: a review.Front. Immunol.20221387076810.3389/fimmu.2022.870768
    [Google Scholar]
11. Allué-GuardiaA. SaranathanR. ChanJ. Mycobacteriophages as potential therapeutic agents against drug-resistant tuberculosis.Int. J. Mol. Sci.202122273510.3390/ijms22020735
    [Google Scholar]
12. HuergaH. KhanU. BastardM. Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid, and other second-line drugs.Clin. Infect. Dis.20227581307131410.1093/cid/ciac176
    [Google Scholar]
13. AkaluT.Y. ClementsA.C.A. WoldeH.F. Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis.Sci. Rep.202313122361
    [Google Scholar]
14. AkaluT.Y. ClementsA.C.A. WoldeH.F. Prevalence of long-term physical sequelae among patients treated with multi-drug and extensively drug-resistant tuberculosis: a systematic review and meta-analysis.EClinicalMedicine202357101900
    [Google Scholar]
15. SinglaR. MallickM. MrigpuriP. Sequelae of pulmonary multidrug-resistant tuberculosis at the completion of treatment.Lung India201835148
    [Google Scholar]